PERFIL EPIDEMIOLÓGICO DO CÂNCER COLORRETAL
Colorretal Cancer Epidemiological Profile
Fernanda Laraia da Rocha Lobo, Auro del Giglio, Pedro da Costa Aguiar.
Resumo
Objetivo: Analisar o perfil dos pacientes com câncer colorretal (CCR) tratados no Hospital Anchieta (HA) e Instituto Brasileiro de Controle do Câncer (IBCC) no período de 2013 a 2018. Métodos: Estudo retrospectivo descritivo no qual foram coletados dados a partir dos prontuários de pacientes com CCR metastáticos ao diagnóstico que fizeram acompanhamento no HA e no IBCC entre 2013 e 2018. Resultados: Dos 60 pacientes, 26,7% tinham neoplasia no cólon ascendente, 3,3% no transverso, 5% no descendente, 35% no sigmóide e 30% no reto. A lateralidade da neoplasia à direita foi encontrada em 30% e 70% apresentou doença à esquerda. Em relação a mutação do KRAS, 30% eram mutados, 40% eram wild type e 30% não tiveram a pesquisa da mutação realizada. A mediana da sobrevida livre de progressão dos pacientes do estudo foi de 11 meses. A mediana da sobrevida global foi de 34 meses, nesse estudo a lateralidade não foi fator prognóstico para SLP com sobrevida ligeiramente maior para pacientes com neoplasia à direita. Em análise multivariada, foi demonstrado que idade inferior a 60 anos, presença da mutação, metástase no peritônio e etnia são fatores de mau prognóstico. Conclusão:. Houve discrepância entre os dados encontrados na literatura e os encontrados no estudo, isso provavelmente se deve ao número pequeno de pacientes incluídos no trabalho. É necessário estudo com um número maior de pacientes para que os dados da literatura sejam semelhantes aos da realidade.
Palavras-chave
Abstract
Objective: To analyze the profile of patients with colorectal cancer (CRC) treated at the Anchieta Hospital (AH) and the Brazilian Institute of Cancer Control (BICC) from 2013 to 2018. Methods: Retrospective descriptive study in which data were collected from medical records of patients with metastatic CRC at diagnosis who were followed up in AH and BICC between 2013 and 2018. Results: Of 60 patients, 26.7% had cancer of the ascending colon, 3.3% of the transverse colon, 5% of the descending colon, 35% of the sigmoid and 30% of the rectum. Right side neoplasia was found in 30% and 70% had left disease. Regarding the KRAS mutation, 30% were mutated, 40% were wild type, and 30% had no mutation screening performed. The median progression-free survival (PFS) of the study patients was 11 months. The median overall survival was 34 months; in this study, laterality was not a prognostic factor for PFS with slightly longer survival for patients with right-sided cancer. Multivariate analysis showed that age below 60 years, presence of mutation, peritoneum metastasis and ethnicity are factors of poor prognosis. Conclusion: There was a discrepancy between the data found in the literature and those found in the study, probably due to the small number of patients included in the study. It is necessary to study with a larger number of patients so that the literature data are similar to the reality data.
Keywords
Referências
1. Instituto Nacional de Câncer. INCA 2018: estimativa: colorretal: casos: taxas: Brasil [Internet]. Brasília; 2018 [citado 2018 jun 20]. Disponível em: http://www1.inca.gov.br/estimativa/2018/casos-taxas-brasil.asp
2. World Health Organization. Estimated number of incident cases worldwide, both sexes, all ages [Internet]. Lyon; 2018 [citado 2018 jun 20]. Disponível em: https://gco.iarc.fr/today/online-analysis-multibars?v=2018&mode=cancer&mode_population=countries&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Afalse%252C%2522mort%2522%253Atrue%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D&population_group_globocan_id=
3. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-91. http://dx.doi.org/10.1136/gutjnl-2015-310912. PMid:26818619.
4. Koch M, McPherson TA, Egedahl RD. Effect of sex and reproductive history on the survival of patients with colorectal cancer. J Chronic Dis. 1982;35(1):69-72. http://dx.doi.org/10.1016/0021-9681(82)90032-7. PMid:7068804.
5. Haas P. Efetividade da ingestão de grãos integrais na prevenção do câncer colorretal: revisão sistemática de estudos de coorte com metanálise [tese]. Florianópolis: Universidade Federal de Santa Catarina; 2007.
6. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus leftsided colon cancers. Ann Surg Oncol. 2008;15(9):2388-94. http://dx.doi.org/10.1245/s10434-008-0015-y. PMid:18622647.
7. Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal câncer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140(8):603-13. http://dx.doi.org/10.7326/0003-4819-140-8-200404200-00007. PMid:15096331.
8. Fagunwa IO, Loughrey MB, Coleman HG. Alcohol, smoking and the risk of premalignant and malignant colorectal neoplasms. Best Pract Res Clin Gastroenterol. 2017;31(5):561-8. http://dx.doi.org/10.1016/j.bpg.2017.09.012. PMid:29195676.
9. Bertolazzi LG, Domingues JL Jr, Carmo VCMFO, Fernandez FLC. Prevalência de diabetes em pacientes com neoplasias malignas de trato intestinal em um hospital de ensino. Rev Bras Oncol Clin. 2015;11(40):71-7.
10. Vasques AR, Peres A. Tendência temporal da mortalidade por câncer de cólon e reto em Santa Catarina no período entre 1980 a 2006. Epidemiol Serv Saude. 2010;19(2):91-100. http://dx.doi.org/10.5123/S1679-49742010000200002.
11. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2017;141(5):625-57. http://dx.doi.org/10.5858/arpa.2016-0554-CP. PMid:28165284.
12. Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33(16):1809-24. http://dx.doi.org/10.1200/JCO.2014.59.7633. PMid:25918280.
13. Zavadsky KE, Lee YT. Liver metastases from colorectal carcinoma: incidence, resectability, and survival results. Am Surg. 1994;60(12):929-33. PMid:7992967.
14. Thomassen I, Van Gestel YR, Lemmens VE, Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritonealcarcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56(12):1373-80. http://dx.doi.org/10.1097/DCR.0b013e3182a62d9d. PMid:24201391.
15. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677-83. http://dx.doi.org/10.1200/JCO.2008.20.5278. PMid:19470929.
16. Tonon LM, Secoli SR, Caponero R. Câncer colorretal: uma revisão da abordagem terapêutica com bevacizumabe. Rev Bras Cancerol. 2007;53(2):173-82.
17. Martoni AA, Tanneberger S, Mutri V. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori. 2007;93(5):417-22. http://dx.doi.org/10.1177/030089160709300502. PMid:18038871.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email